

Index

- 5-HT₃ receptor antagonist, 1039
- 6-mercaptopurine, 395
- 6-methylprednisolone, 263
- 6-thioguanine nucleotides, 401, 917
- Abdoolah, A. *see* Ahmad, I.
- Abreu, M.T. *see* Papadakis, K.A.
- acetaminophen, 979
- achalasia, 1
- acid perception, 605
- acid suppressing drugs, 973
- acid suppression, 544
- acid suppression therapy, 693
- Adam, B. *see* Holtmann, G.
- adherence, 1139
- adherent-invasive *E. coli*, 45
- adverse events, 451
- Ahmad, I., Mouncher, A., Abdoolah, A., Stenson, R., Wright, J., Daniels, A., Tillett, J., Hawthorne, A.B. & Thomas, G.
Antibiotic prophylaxis for percutaneous endoscopic gastrostomy — a prospective, randomised, double-blind trial, 209
- AIEC, 45
- Akbari, M.R. *see* Shahbazkhani, B.
- alcoholic liver disease, 357
- alcoholism, 357
- alendronate, 1121
- Allan, R.B. *see* Field, E.A.
- Allez, M. *see* Sabaté, J.-M.
- Allocca, M. *see* Cantù, P.
- Almog, S. *see* Kurnik, D.
- alpha-IFN, 549
- alternative medicine, 451
- anal fissure, 1, 1173
- Anderson, J. *see* Creed, T.J.
- Andersson, T. *see* Sostek, M.B.
- Andreyev, H.J.N. *see* Gami, B.
- Andriulli, A. *see* Niro, G.A.
- Andriulli, A. *see* Perri, F.
- Angelico, M. *see* Petrolati, A.
- antacids, 291
- antibiotic prophylaxis, 209
- antibiotic safety testing, 821
- antibiotics, 815, 947, 1113
- antibiotics-only, 93
- antimicrobial resistance, 799
- anti-TNF α , 917
- antroduodenal manometry, 1039
- anxiety, 319
- anxiety and depression, 595
- aphthous stomatitis, 949
- Ardizzone, S. *see* Maconi, G.
- Areni, A. *see* Calabrese, C.
- Arlander, E., Cederlund, T. & Måre, K. No volume effect on retrograde colonic spread of rectally-administered ropivacaine gel, 655
- Armstrong, D., Bair, D., James, C., Tanser, L., Escobedo, S. & Nevin, K. Oral esomeprazole vs. intravenous pantoprazole: a comparison of the effect on intragastric pH in healthy subjects, 705
- artichoke, 1099
- artificial liver, 473
- Asaka, M. *see* Gené, E.
- aspirin, 109, 443
- Atisook, K. *see* Kositchaiwat, C.
- atrophic gastritis, 245
- autoimmunity, 549
- Azagra, R. *see* Gené, E.
- azathioprine, 917, 1113
- azathioprine/mercaptopurine, 401
- azathiopurine, 395
- baclofen, 199
- bacterial overgrowth, 1107
- bacterial resistance, 821
- Bair, D. *see* Armstrong, D.
- Balatsinou, C. *see* Neri, M.
- Barabino, A. *see* Lionetti, P.
- Barberani, F. *see* Perri, F.
- Barclay, M.L. *see* Geary, R.B.
- Bar-Meir, S. *see* Kurnik, D.
- Barnes, D.S. *see* Saadeh, S.
- Barthelemy (for a Multicentre Study Group), P. *see* Lamouliatte, H.
- Bartram, S.A., Peaston, R.T., Rawlings, D.J., Francis, R.M. & Thompson, N.P. A randomized controlled trial of calcium with vitamin D, alone or in combination with intravenous pamidronate, for the treatment of low bone mineral density associated with Crohn's disease, 1121
- Bascietto, C. *see* Lionetti, P.
- basiliximab, 65
- Bästlein, E. *see* Miehke, S.
- Bayerdörffer, E. *see* Miehke, S.
- Bazzoli, F. *see* Leodolter, A.
- Beales, I.L.P. & McGovern, J. Letter to the Editors, 947
- Beattie, R.M. *see* Trebble, T.M.
- Behçet's disease, 949
- Behrens, P.W. *see* Saadeh, S.
- Belaiche, J. *see* Bonaz, B.
- Bell, S.J., Chisholm, S.A., Owen, R.J., Borriello, S.P. & Kamm, M.A.
Evaluation of *Helicobacter* species in inflammatory bowel disease, 481
- Bellissant, E. *see* Madalinski, M.
- Bellissant, E. *see* Siprodhis, L.

- Bergey, B., Marchildon, P., Peacock, J. & Mégraud, F. What is the role of serology in assessing *Helicobacter pylori* eradication?, 635
- Berni Canani, R. *see* Lionetti, P.
- Berstad, A. *see* Tytgat, G.N.
- Bessard, G. *see* Roblin, X.
- Betterle, C. *see* Fabris, P.
- Beuers, U. *see* Hempling, W.
- Béziau, S. *see* Buecher, B.
- Bianchi Porro, G. *see* Maconi, G.
- Bianchi Porro, G. *see* Parente, F.
- Bianco, R. *see* Parente, F.
- bile formation and cholestasis, 963
- biliary colic, 333
- biliary disorders, 546, 995
- biopsy, 481
- bisphosphonates, 1121
- Bitton, A. *see* Wild, G.E.
- Björkman, A. *see* Wheelon, T.-U.
- Bjorkman, D. *see* Inadomi, J.M.
- Blackshaw, E. *see* Coleman, N.S.
- Blake, P. *see* Gami, B.
- blood, 927
- Blottière, H.M. *see* Buecher, B.
- Blum, A.L. *see* Pantolickova, D.
- Boesiger, P. *see* Steingoetter, A.
- van den Bogaard, A. *see* Goossens, D.
- Boitard, J. *see* Bonaz, B.
- Bolling-Sternevald, E., Lauritsen, K., Talley, N.J., Junghard, O. & Glise, H. Is it possible to predict treatment response to a proton pump inhibitor in functional dyspepsia? 117
- Bonaz, B. *see* Roblin, X.
- Bonaz, B., Boitard, J., Marteau, P., Lémann, M., Coffin, B., Flourié, B., Belaiche, J., Cadiot, G., Metman, E.-H., Cortot, A., Colombel, J.-F. & Getaïd, Tioguanine in patients with Crohn's disease intolerant or resistant to azathioprine/mercaptopurine, 401
- bone mineral density, 1121
- bone resorption, 1121
- Borgaonker, M. *see* Dunlop, S.P.
- Borjesson, M., Rohy, P., Mannheimer, C. & Pilhall, M. Nutcracker oesophagus: a double-blind, placebo-controlled, cross-over study of the effects of lansoprazole, 1129
- Borriello, S.P. *see* Bell, S.J.
- Bortolotti, M. *see* Calabrese, C.
- botulinum toxin, 1, 515, 1173
- Boudeau, J., Glasser, A.-L., Julien, S., Colombel, J.-F. & Darfeuille-Michaud, A. Inhibitory effect of probiotic *Escherichia coli* strain Nissle 1917 on adhesion to and invasion of intestinal epithelial cells by adherent-invasive *E. coli* strains isolated from patients with Crohn's disease, 45
- Bouhnik, Y. *see* Gornet, J.-M.
- Bouhnik, Y. *see* Sabaté, J.-M.
- bowel ultrasound, 1009
- branched-chain amino acids, 357
- Branson, J. *see* Rordorf, C.
- breath test, 927
- breath tests, 721
- Bredenoord, A.J. *see* Delgado-Aros, S.
- Bretagne, J.-F. *see* Lamouliatte, H.
- Briggs, A. *see* Tytgat, G.N.
- Bronzini, F. *see* Lionetti, P.
- Buchner, M. *see* Miehke, S.
- Buckley, M.J.M. *see* Sebastian, S.
- budesonide, 263
- Buecher, B., Heymann, M.-F., Lièvre, A., Nguyen, J.-M., Wilson, K., Bézieau, S., Mosnier, J.-F., Galmiche, J.-P. & Blottière, H.M. Cyclo-oxygenase-2 over-expression in sporadic colorectal carcinoma without lymph node involvement, 731
- Bunnapradist, S. *see* Fabrizi, F.
- Burke, T.A. *see* Sturkenboom, M.C.J.M.
- Burt, M.J. *see* Gearry, R.B.
- Burton, D.D. *see* Delgado-Aros, S.
- Bytzer, P. *see* Corazzari, E.
- Cadiot, G. *see* Bonaz, B.
- Calabrese, C., Fabbri, A., Bortolotti, M., Cenacchi, G., Areni, A., Scialpi, C., Miglioli, M. & Di Febo, G. Dilated intercellular spaces as a marker of oesophageal damage: comparative results in gastro-oesophageal reflux disease with or without bile reflux, 525
- Caldarella, M.P. *see* Neri, M.
- Calvet, X. *see* Gené, E.
- Calvet, X. *see* Gisbert, J.P.
- Calvet, X. *see* Vergara, M.
- Camilleri, M. *see* Cremonini, F.
- Camilleri, M. *see* Delgado-Aros, S.
- Camarota, G. *see* Nista, E.C.
- Candelli, M. *see* Madalinski, M.
- Candelli, M. *see* Nista, E.C.
- Cantù, P., Carmagnola, S., Savojardo, D., Allocca, M. & Penagini, R. Effect of non-selective γ -aminobutyric acid receptor stimulation on motor function of the lower oesophageal sphincter and gastro-oesophageal reflux in healthy human subjects, 699
- Carballo, F. *see* Gisbert, J.P.
- carbonic anhydrase IX, 837
- cardiovascular disease, 109
- Carey, W.D. *see* Saadeh, S.
- Carlioni, E. *see* Nista, E.C.
- Carmagnola, S. *see* Cantù, P.
- Carotti, S. *see* Cicala, M.
- Carsana, L. *see* Maconi, G.
- Castell, D.O. *see* Katz, P.O.
- Castiglione, F., Rispo, A., Di Girolamo, E., Cozzolino, A., Manguso, F., Grassia, R. & Mazzacca, G. Antibiotic treatment of small bowel bacterial overgrowth in patients with Crohn's disease, 1107
- Caviglia, R. *see* Cicala, M.
- Cazzato, I.A. *see* Madalinski, M.
- Cazzato, I.A. *see* Nista, E.C.
- Cederlund, T. *see* Arlander, E.
- cefuroxime, 947
- celecoxib, 217
- celiac disease, 231

- Cenacchi, G. *see* Calabrese, C.
 Chakraborty, A. *see* Trebble, T.M.
 Chan, A.O.O. *see* Cheng, C.
 Chan, H.L.-Y., Sung, J.J.-Y., Fong, W.-F., Chim, A.M.-L., Yung, P.-P., Hui, A.Y., Fung, K.-P. & Leung, P.-C. Double-blinded placebo-controlled study of *Phyllanthus urinaris* for the treatment of chronic hepatitis, 339
 Chan, C.K. *see* Lai, K.C.
 Chan, C.K. *see* Wong, B.C.-Y.
 Chan, C.K. *see* Wong, W.M.
 Chan, F.K.L. *see* Lee, K.K.C.
 Chan, O.O. *see* Lai, K.C.
 Chan, P.Q. *see* Coleman, N.S.
 Chang, C.M. *see* Ng, F.H.
 Chang, F.-Y. *see* Lu, C.-L.
 Chapman, B.A. *see* Geary, R.B.
 Chaussade, S. *see* Tytgat, G.N.
 chemotherapy, 853, 1049
 Chen, C.-Y. *see* Lu, C.-L.
 Chen, J. *see* Juhász, M.
 Chen, W.H. *see* Ng, F.H.
 Chen, Y. *see* Sostek, M.B.
 Cheng, C., Chan, A.O.O., Hui, W.M. & Lam, S.K. Coping strategies, illness perception, anxiety and depression of patients with idiopathic constipation: a population-based study, 319
 chest pain, 1083
 Cheung, K.L. *see* Wong, B.C.-Y.
 Chi, C.-H., Lin, C.-Y., Sheu, B.-S., Yang, H.-B., Huang, A.-H. & Wu, J.-J. Quadruple therapy containing amoxicillin and tetracycline is an effective regimen to rescue failed triple therapy by overcoming the antimicrobial resistance of *Helicobacter pylori*, 347
 Chial, H.J. *see* Delgado-Aros, S.
 Child-Pugh score, 785
 Chim, A.M.-L. *see* Chan, H.L.-Y.
 Chisholm, S.A. *see* Bell, S.J.
 cholecystectomy, 167
 cholecystokinin receptors, 333
 Chowers, Y. *see* Kurnik, D.
 chronic anal fissure, 515
 chronic hepatitis, 549
 chronic hepatitis C, 661
 Chu, K.M. *see* Lai, K.C.
 Chu, K.W. *see* Wong, B.C.-Y.
 Cicala, M., Emerenziani, S., Caviglia, R., Guarino, M.P.L., Vavassori, P., Ribolsi, M., Carotti, S., Petitti, T. & Pallone, F. Intra-oesophageal distribution and perception of acid reflux in patients with non-erosive gastro-oesophageal reflux disease, 605
 ciprofloxacin, 263, 1107
 clarithromycin, 347, 799
 clarithromycin resistance, 791
 clinical trial, 569, 791
 clopidogrel, 443
 Colfin, B. *see* Bonaz, B.
 cohort study, 973
 Colaiocco-Ferrante, L. *see* Petrolati, A.
 Coleman, N.S., Marciani, L., Blackshaw, E., Wright, J., Parker, M., Yano, T., Yamazaki, S., Chan, P.Q., Wilde, K., Gowland, P.A., Perkins, A.C. & Spiller, R.C. Effect of a novel 5-HT₃ receptor agonist on upper gastrointestinal motility in humans, 1039
 colitis, 415
 Collet, W. *see* Holtmann, G.
 Collett, J.A. *see* Geary, R.B.
 Collins, S.M. *see* Dunlop, S.P.
 Colombel, J.-F. *see* Bonaz, B.
 Colombel, J.-F. *see* Boudeau, J.
 colon cancer, 941
 colorectal cancer, 731
 colorectal neoplasia, 941
 complementary therapy, 987
 compliance, 191
 complicated reflux disease, 1091
 Connor, J.T. *see* Saadeh, S.
 constipation, 291, 319, 1161
 coping strategies, 319
 Corazzari, E., Bytzer, P., Delvaux, M., Holtmann, G., Malagelada, J.R., Morris, J., Muller-Lissner, S., Spiller, R.C., Tack, J. & Whorwell, P.J. Consensus report: clinical trial guidelines for pharmacological treatment of irritable bowel syndrome, 569
 Corthésy-Theulaz, I. *see* Pantolickova, D.
 corticosteroids, 263
 Cortot, A. *see* Bonaz, B.
 Cosnes, J. *see* Gornet, J.-M.
 cost analysis, 217
 Courillon-Mallet, A. *see* Lamouliatte, H.
 Couve, S. *see* Gornet, J.-M.
 COX-2 expression, 731
 COX-2 specific inhibitor, 125
 Coyne, K.S., Wiklund, I., Schmier, J., Halling, K., Degl' Innocenti, A. & Revicki, D. Development and validation of a disease-specific treatment satisfaction questionnaire for gastro-oesophageal reflux disease, 907
 Cozzolino, A. *see* Castiglione, F.
 Creed, T.J., Norman, M.R., Probert, C.S.J., Harvey, R.F., Shaw, I.S., Smithson, J., Anderson, J., Moorghean, M., Gupta, J., Shepherd, N.A., Dayan, C.M. & Hearing, S.D. Basiliximab (anti-CD25) in combination with steroids may be an effective new treatment for steroid-resistant ulcerative colitis, 65
 Cremonini, F. *see* Delgado-Aros, S.
 Cremonini, F. *see* Nista, E.C.
 Cremonini, F., Di Caro, S., Delgado-Aros, S., Sepulveda, A., Gasbarrini, G., Gasbarrini, A. & Camilleri, M. Meta-analysis: the relationship between *Helicobacter pylori* infection and gastro-oesophageal reflux disease, 279
 cricopharyngeal achalasia, 1
 Cristaldi, M. *see* Maconi, G.
 Cristaldi, M. *see* Parente, F.
 Crohn's disease, 45, 57, 309, 395, 401, 409, 425, 433, 481, 741, 749, 917, 1003, 1009, 1107, 1113, 1121
 Cuccurullo, F. *see* Neri, M.
 Cucino, C. *see* Parente, F.
 CYP 2C19, 101
 CYP1A2, 979

CYP2C19, 1151

cytokines, 309

- Dalhoff, K. *see* Schmidt, L.E.
 D'Amato, M. *see* Malesci, A.
 Danelli, P.G. *see* Parente, F.
 Daniels, A. *see* Ahmad, I.
 Darfeuille-Michaud, A. *see* Boudeau, J.
 Davies, J. *see* Gami, B.
 Davis, K., Kumar, D. & Poloniecki, J. Preliminary evaluation of an injectable anal sphincter bulking agent (Durasphere) in the management of faecal incontinence, 237
 Dayan, C.M. *see* Creed, T.J.
 Dé Angelis, G.L. *see* Lionetti, P.
 De Berardinis, G. *see* Petrolati, A.
 De Francesco, V. *see* Hassan, C.
 De Garmo, P. *see* Dekel, R.
 De Korwin, J.-D. *see* Lamouliatte, H.
 De Micheli, E. *see* Frazzoni, M.
 Dearnaley, D. *see* Gami, B.
 Degl' Innocenti, A. *see* Coyne, K.S.
 Deibert, P., Dilger, K., Fischer, C., Hofmann, U., Nauck, S., Stoelben, S. & Kreisel, W. High variation of tioguanine absorption in patients with chronic active Crohn's disease, 183
 Dejaco, C., Harrer, M., Waldhoer, T., Miehsler, W., Vogelsang, H. & Reinisch, W. Antibiotics and azathioprine for the treatment of perianal fistulas in Crohn's disease, 1113
 Dekel, R., Pearson, T., Wendel, C., De Garmo, P., Fennerty, M.B. & Fass, R. Assessment of oesophageal motor function in patients with dysphagia or chest pain — the Clinical Outcomes Research Initiative experience, 1083
 Delchier, J.-C. *see* Gornet, J.-M.
 Delchier, J.-C. *see* Lamouliatte, H.
 Delgado-Aros, S. *see* Cremonini, F.
 Delgado-Aros, S., Chial, H.J., Cremonini, F., Ferber, I., McKinzie, S., Burton, D.D. & Camilleri, M. Effects of asimadoline, a κ -opioid agonist, on satiation and postprandial symptoms in health, 507
 Delgado-Aros, S., Cremonini, F., Bredenoord, A.J. & Camilleri, M. Systematic review and meta-analysis: does gall-bladder ejection fraction on cholecystokinin cholescintigraphy predict outcome after cholecystectomy in suspected functional biliary pain? 167
 Delvaux, M. *see* Corazziari, E.
 Demleitner, K. *see* Malferttheiner, P.
 detection, 481
 developing country, 93
 Di Bonaventura, G. *see* Neri, M.
 Di Campli, C., Gasbarrini, G. & Gasbarrini, A. Review article: a medicine based on cell transplantation — is there a future for treating liver diseases? 473
 Di Caro, S. *see* Cremonini, F.
 Di Caro, S. *see* Nista, E.C.
 Di Febo, G. *see* Calabrese, C.
 Di Girolamo, E. *see* Castiglione, F.
 Di Paolo, D. *see* Petrolati, A.
 diabetes, 549
 diagnosis, 927
 dialysis, 1071
 diarrhoea, 1161
 Dieleman, J.P. *see* Sturkenboom, M.C.J.M.
 diet, 987
 Dijkstra, G. *see* Haagsma, E.B.
 dilatation, 409
 dilated intercellular spaces, 525
 Dilger, K. *see* Deibert, P.
 Dilger, K. *see* Hempling, W.
 disease activity, 749
 Dixit, V. *see* Fabrizi, F.
 dopamine receptor, 151
 Doppler ultrasound, 777
 Dorta, G. *see* Pantolickova, D.
 double-blind placebo-controlled trial, 495
 drug delivery, 713
 drug therapy, 777
 Dubois, D. *see* Revicki, D.A.
 Dulai, G. *see* Fabrizi, F.
 Duncan, M. & Grant, G. Review article: oral and intestinal mucositis — causes and possible treatments, 853
 Dunlop, S.P., Jenkins, D., Neal, K.R., Naesdal, J., Borgaonker, M., Collins, S.M. & Spiller, R.C. Randomized, double-blind, placebo-controlled trial of prednisolone in post-infectious irritable bowel syndrome, 77
 duodenal ulcer, 641
 duodenogastroesophageal reflux, 525
 Dupas, J.-L. *see* Gornet, J.-M.
 duration, 85
 dynamicity, 151
 dyspepsia, 117, 223
 dysphagia, 1083
 dysport, 1173
 Ebert, M.P.A. *see* Juhász, M.
 Ebert, S. *see* Miehlke, S.
 echoplanar magnetic resonance imaging, 1039
 efficacy, 559
 elderly, 125
 Ellidokuz, E. & Kaya, D. The effect of metoclopramide on QT dynamicity: double-blind, placebo-controlled, cross-over study in healthy male volunteers, 151
 El-Serag, H.B. & Talley, N.J. Systematic review: health-related quality of life in functional dyspepsia, 387
 Emerenziani, S. *see* Cicala, M.
 Emmanuel, A.V. *see* Rayner, C.K.
 endoscopic ultrasonography, 327
 endoscopy, 125, 409, 533
 Enjoji, A. *see* Isomoto, H.
 Enslen, M. *see* Pantolickova, D.
 enterochromaffin cell, 77
 enzyme induction, 979
 eradication, 245, 635, 815
 eradication therapy, 1023
 Ergun, G. *see* Liu, L.
 Erlewyn-Lajeunesse, M.D.S. *see* Trebble, T.M.

- Ernst, E. *see* Pittler, M.H.
erosive reflux oesophagitis, 1091
 Ertan, A. *see* Liu, L.
 Escobedo, S. *see* Armstrong, D.
 Eslick, G.D. *see* Gené, E.
esomeprazole, 587, 705, 767, 799, 875
essential fatty acid, 433
- Fabbri, A. *see* Calabrese, C.
 Fabris, P., Floreani, A., Tositti, G., Vergani, D., de Lalla, F. & Betterle, C. Review article: type 1 diabetes mellitus in patients with chronic hepatitis C before and after interferon therapy, 549
 Fabrizi, F., Dulai, G., Dixit, V., Bunnapradist, S. & Martin, P. Meta-analysis: interferon for the treatment of chronic hepatitis C in dialysis patients, 1071
 Facciorusso, D. *see* Niro, G.A.
faecal bacterial composition, 495
faecal incontinence, 237
failure, 815
 Färkkilä, M. *see* Heikkinen, M.
 Fass, R. *see* Dekel, R.
 Fauchère, J.-L. *see* Lamouliatte, H.
 Feagan, B.G. *see* Sandborn, W.J.
 Fennerty, M.B. *see* Dekel, R.
 Fennerty, M.B. *see* Inadomi, J.M.
 Fennerty, M.B. *see* Vakil, N.
 Fennerty, M.B. *see* Zaman, A.
 Ferber, I. *see* Delgado-Aros, S.
 Ferguson, J.W., Tripathi, D. & Hayes, P.C. Review article: the management of acute variceal bleeding, 253
fermented milk, 805
 Festa, V. *see* Perri, F.
 Festi, D. *see* Petrolati, A.
 Field, E.A. & Allan, R.B. Review article: oral ulceration – aetiopathogenesis, clinical diagnosis and management in the gastrointestinal clinic, 949
 Fischbach, W. *see* Malfertheiner, P.
 Fischer, C. *see* Deibert, P.
 Fishbein, E. *see* Kurnik, D.
fistula drainage assessment, 1113
fistulas, 1003
 Fléjou, J.-F. *see* Lamouliatte, H.
 Fleshner, P.R. *see* Papadakis, K.A.
 Floreani, A. *see* Fabris, P.
 Flourié, B. *see* Bonaz, B.
 Fociani, P. *see* Maconi, G.
 Fong, W.-F. *see* Chan, H.L.-Y.
 Fontana, R. *see* Niro, G.A.
 Ford, M. *see* Rordorf, C.
 Forootan, M. *see* Shahbazkhani, B.
 Francis, R.M. *see* Bartram, S.A.
 Frazzoni, M., De Micheli, E. & Savarino, V. Different patterns of oesophageal acid exposure distinguish complicated reflux disease from either erosive reflux oesophagitis or non-erosive reflux disease, 1091
 Fried, M. *see* Steingøetter, A.
 Fried, M. *see* Tytgat, G.N.
 Fuchs, W. *see* Malfertheiner, P.
 Fujimoto, C. *see* Isomoto, H.
functional dyspepsia, 117, 223, 387, 1099
functional foods, 721
functional gastrointestinal, 507
functional GI disorders, 167
 Fung, K.-P. *see* Chan, H.L.-Y.
 Furusu, H. *see* Isomoto, H.
 Furuta, T. *see* Madalinski, M.
- GABA, 699
 GABA_B agonist, 199
 Gabriel, R. *see* Gisbert, J.P.
 Gabrielli, M. *see* Nista, E.C.
galactose breath test, 995
 Gallo-Torres, H. *see* Gardner, J.D.
gallstone disease, 333
 Gallus, S. *see* Parente, F.
 Galmiche, J.-P. *see* Buecher, B.
 Gami, B., Harrington, K., Blake, P., Dearnaley, D., Tait, D., Davies, J., Norman, A.R. & Andreyev, H.J.N. How patients manage gastrointestinal symptoms after pelvic radiotherapy, 987
 García Rodríguez, L.A. *see* Johansson, S.
 Gardner, J.D., Gallo-Torres, H., Sloan, S., Robinson, M. & Miner Jr, P.B. The basis for the decreased response to proton pump inhibitors in gastro-oesophageal reflux disease patients without erosive oesophagitis, 891
 Gardner, J.D., Sloan, S., Robinson, M. & Miner Jr, P.B. Heartburn severity can predict pathologic oesophageal reflux in gastro-oesophageal reflux disease patients treated with a proton-pump inhibitor, 133
 Garrido-Serrano, A. *see* Romero-Gómez, M.
 Gasbarrini, A. *see* Cremonini, F.
 Gasbarrini, A. *see* Di Campli, C.
 Gasbarrini, A. *see* Madalinski, M.
 Gasbarrini, A. *see* Nista, E.C.
 Gasbarrini, G. *see* Cremonini, F.
 Gasbarrini, G. *see* Di Campli, C.
 Gasbarrini, G. *see* Nista, E.C.
gastric accommodation, 1031
gastric accommodation, 507
gastric acid, 587
gastric barostat, 1031
gastric emptying, 1039
gastric pH, 545, 705, 891
gastric sensitivity, 1031
gastric ulcer, 544
gastritis, 805
gastrointestinal safety, 125
gastrointestinal symptom rating scale, 587
gastro-oesophageal reflux, 699, 883, 973
gastro-oesophageal reflux disease, 117, 291, 525, 545, 587, 595, 605, 693, 767, 875, 891, 907
gastroparesis cardinal symptom index, 141
 Gatz, G. *see* Scholten, T.

- Gearry, R.B., Barclay, M.L., Burt, M.J., Collett, J.A., Chapman, B.A., Roberts, R.L. & Kennedy, M.A. Thiopurine S-methyltransferase (TPMT) genotype does not predict adverse drug reactions to thiopurine drugs in patients with inflammatory bowel disease, 395
- Geboes, K.P., Luybaerts, A., Rutgeerts, P. & Verbeke, K. Inulin is an ideal substrate for a hydrogen breath test to measure the oro-caecal transit time, 721
- Geerts, A. *see* Reynaert, H.
- gene therapy, 473
- Gené, E., Calvet, X., Azagra, R., Gisbert, J.P., Howell, S.C., Eslick, G.D., Sugiyama, T., Asaka, M., Sozzi, M., Queiroz, D.M.M., Oliveira, A.G., Guerra, J.B., Lima, J.C.P., Silva, C.P. & Rocha, G.A. Letters to the Editors, 543
- Ghaneh, P. *see* Shore, S.
- Gill, S., Thomas, R.R. & Goldberg, R.M. Review article: colorectal cancer chemotherapy, 683
- Gioffreda, D. *see* Niro, G.A.
- Gisbert, J.P. *see* Gené, E.
- Gisbert, J.P. *see* Vergara, M.
- Gisbert, J.P., Khorrami, S., Calvet, X., Gabriel, R., Carballo, F. & Pajares, J.M. Meta-analysis: proton pump inhibitors vs. H₂-receptor antagonists — their efficacy with antibiotics in *Helicobacter pylori* eradication, 757
- Glasser, A.-L. *see* Boudeau, J.
- Glise, H. *see* Bolling-Sternevald, E.
- gluten free diet, 231
- Goerres, M.S., Meijer, J.W.R., Wahab, P.J., Kerckhaert, J.A.M., Groenen, P.J.T.A., van Krieken, J.H.J.M. & Mulder, C.J.J. Azathioprine and prednisone combination therapy in refractory coeliac disease, 487
- Goldberg, R.M. *see* Gill, S.
- Goldstein, J.L. *see* Sturkenboom, M.C.J.M.
- Goldstein, J.L., Kivitz, A.J., Verburg, K.M., Recker, D.P., Palmer, R.C. & Kent, J.D. A comparison of the upper gastrointestinal mucosal effects of valdecoxib, naproxen and placebo in healthy elderly subjects, 125
- Goossens, D., Jonkers, D., Russel, M., Stobberingh, E., van den Bogaard, A. & Stockbrügger, R. The effect of *Lactobacillus plantarum* 299v on the bacterial composition and metabolic activity in faeces of healthy volunteers: a placebo-controlled study on the onset and duration of effects, 495
- Gornet, J.-M. *see* Sabaté, J.-M.
- Gornet, J.-M., Couve, S., Hassani, Z., Delchier, J.-C., Marteau, P., Cosmes, J., Bouhnik, Y., Dupas, J.-L., Modigliani, R., Taillard, F. & Lemann, M. Infliximab for refractory ulcerative colitis or indeterminate colitis: an open-label multicentre study, 175
- Gowland, P.A. *see* Coleman, N.S.
- graft reperfusion, 785
- Granström, M. *see* Wheeldon, T.-U.
- Grant, G. *see* Duncan, M.
- Grassia, R. *see* Castiglione, F.
- Grealis, M. *see* Saadeh, S.
- Greco, S. *see* Parente, F.
- Groenen, P.J.T.A. *see* Goerres, M.S.
- growth/development/nutrition, 721
- Grünewald, E. *see* Holtmann, G.
- Guarino, M.P.L. *see* Cicala, M.
- Guariso, G. *see* Lionetti, P.
- Guastadisegni, A. *see* Niro, G.A.
- Guerra, J.B. *see* Gené, E.
- Gui, D., Rossi, S., Runfola, M. & Magalini, S.C. Review article: botulinum toxin in the therapy of gastrointestinal motility disorders, 1
- Gupta, J. *see* Creed, T.J.
- H² receptor antagonist, 757, 847
- Haag, S. *see* Holtmann, G.
- Haagsma, E.B., Van Den Berg, A.P., Kleibeuker, J.H., Slooff, M.J.H. & Dijkstra, G. Inflammatory bowel disease after liver transplantation: the effect of different immunosuppressive regimens, 33
- Haferland, C. *see* Mielke, S.
- Halkin, H. *see* Kurnik, D.
- Halling, K. *see* Coyne, K.S.
- Harrer, M. *see* Dejac, C.
- Harrington, K. *see* Gami, B.
- Haruma, K. *see* Kamada, T.
- Harvey, R.F. *see* Creed, T.J.
- Hassan, C., De Francesco, V., Zullo, A., Scaccianoce, G., Piglionica, D., Ierardi, E., Panella, C. & Morini, S. Sequential treatment for *Helicobacter pylori* eradication in duodenal ulcer patients: improving the cost of pharmacotherapy, 641
- Hassani, Z. *see* Gornet, J.-M.
- Hata, J. *see* Kamada, T.
- Hawthorne, A.B. *see* Ahmad, I.
- Hayes, P.C. *see* Ferguson, J.W.
- HBV DNA, 339
- Heading, R.C. *see* Tytgat, G.N.
- health care utilisation, 595
- health economics, 671
- health research quality of life, 387
- healthy volunteers, 495
- Hearing, S.D. *see* Creed, T.J.
- heartburn, 587
- Heikkinen, M. & Färkkilä, M. What is the long-term outcome of the different subgroups of functional dyspepsia? 223
- Helicobacter*, 481, 543, 546
- Helicobacter pylori*, 101, 125, 245, 279, 627, 635, 641, 757, 799, 805, 815, 821, 829, 927, 1017
- Helicobacter pylori* culture, 347
- Helicobacter pylori* eradication, 279, 544, 791
- Helicobacter pylori* infection, 93
- Hémery, P. *see* Siprodhis, L.
- Hempfling, W., Dilger, K. & Beuers, U. Systematic review: ursodeoxycholic acid — adverse effects and drug interactions, 963
- hepatitis B, 339
- hepatitis B virus, 549, 933
- hepatitis C, 1071
- hepatitis C virus, 549
- hepatocyte transplantation, 473
- hepatotoxicity, 451, 963, 979
- herbal, 1099

- herbal medicine, 451
- Hergueta, P. *see* Romero-Gómez, M.
- Heymann, M.-F. *see* Buecher, B.
- Hinterleitner, T.A. *see* Högenauer, C.
- Hirakata, Y. *see* Isomoto, H.
- Hirschl, A. *see* Leodolter, A.
- histamine-2-receptor antagonists, 1139
- histology, 749
- Ho, J. *see* Wong, B.C.-Y.
- Ho, J.J. *see* Madalinski, M.
- Ho, J.T.S. *see* Lee, K.K.C.
- Hoang, T.T.H. *see* Wheeldon, T.-U.
- Hoehn, B. *see* Stickel, F.
- Hofmann, U. *see* Deibert, P.
- Högenauer, C., Wenzl, H.H., Hinterleitner, T.A. & Petritsch, W.
Effect of oral tacrolimus (FK 506) on steroid-refractory
moderate/severe ulcerative colitis, 415
- Hole, U. *see* Scholten, T.
- Holtmann, G. *see* Corazziari, E.
- Holtmann, G., Adam, B., Haag, S., Collet, W., Grünewald, E. &
Windeck, T. Efficacy of artichoke leaf extract in the treatment
of patients with functional dyspepsia: a six-week placebo-
controlled, double-blind, multicentre trial, 1099
- Horikawa, Y. *see* Shimatani, T.
- Howell, S.C. *see* Gené, E.
- Hu, H.C. *see* Lai, K.C.
- Hu, W.H.C. *see* Wong, B.C.-Y.
- Hu, W.H.C. *see* Wong, W.M.
- Huang, A.-H. *see* Chi, C.-H.
- Huang, J.Q. *see* Wong, W.M.
- Hui, A.Y. *see* Chan, H.L.-Y.
- Hui, W.M. *see* Cheng, C.
- Hui, W.M. *see* Lai, K.C.
- Hui, W.M. *see* Wong, W.M.
- Ierardi, E. *see* Hassan, C.
- IgG antibodies, 927
- Iishi, H. *see* Sakai, N.
- ileal pouch-anal anastomosis, 741
- immunohistochemistry, 693
- immunology and microbiology, 17, 65, 1023
- immunosuppressant, 303
- immunosuppressive agents, 33
- Inadomi, J.M., Fennerty, M.B. & Bjorkman, D. Systematic review:
the economic impact of irritable bowel syndrome, 671
- indeterminate colitis, 175, 741
- inflammation, 853
- inflammatory bowel disease, 17, 33, 183, 191, 303, 395, 415, 741,
1003, 1009, 1121
- inflammatory disorders, 17, 65, 183, 309, 415, 1023
- infliximab, 175, 425, 741
- Inokuchi, H. *see* Madalinski, M.
- Inoue, K. *see* Isomoto, H.
- Inoue, M. *see* Shimatani, T.
- Insalata, M. *see* Niro, G.A.
- integrated acidity, 891
- interferon, 1071
- interferon therapy, 661
- internal anal sphincter, 237
- intestinal disorders, 17, 65, 77, 183, 415, 671, 749, 1023, 1173
- intestinal epithelial cells, 45
- intestinal permeability, 309
- intestine, 85
- intestine, 853
- intractable ulcer, 544
- irritable bowel syndrome, 231, 671, 1161
- Ishizaki, T. *see* Madalinski, M.
- Isler, P. *see* Pantolickova, D.
- Isomoto, H., Inoue, K., Furusu, H., Enjoji, A., Fujimoto, C.,
Yamakawa, M., Hirakata, Y., Omagari, K., Mizuta, Y., Murase,
K., Shimada, S., Murata, I. & Kohno, S. High-dose rabeprazole-
amoxicillin versus rabeprazole-amoxicillin-metronidazole as
second-line treatment after failure of the Japanese standard
regimen for *Helicobacter pylori* infection, 101
- Ito, M. *see* Kamada, T.
- Izumiya, T. *see* Madalinski, M.
- James, C. *see* Armstrong, D.
- Jansen, J.B.M.J. *see* Laheij, R.J.F.
- Janssen, M.J.R. *see* Laheij, R.J.F.
- Janssens, J. *see* Lee, K.-J.
- Janssens, J. *see* Tack, J.
- Jaspersen, D. *see* Kulig, M.
- Jaulfret, S. *see* Tack, J.
- Jenkins, D. *see* Dunlop, S.P.
- Jewell, D. *see* Tytgat, G.N.
- Johansson, S., Wallander, M.-A., Ruigómez, A. & García
Rodríguez, L.A. Is there any association between myocardial
infarction, gastro-oesophageal reflux disease and acid-
suppressing drugs? 973
- Jonkers, D. *see* Goossens, D.
- Juguet, F. *see* Siprodhis, L.
- Juhász, M., Chen, J., Lendeckel, U., Kellner, U., Kasper, H.-U.,
Tulassay, Z., Pastorekova, S., Malfertheiner, P. & Ebert, M.P.A.
Expression of carbonic anhydrase IX in human pancreatic
cancer, 837
- Julien, S. *see* Boudeau, J.
- Jung, H.C. *see* Kim, S.G.
- Junghard, O. *see* Bolling-Sternevald, E.
- Kachintorn, U. *see* Kositchaiwat, C.
- Kahrilas, P. *see* Revicki, D.A.
- Kamada, T., Haruma, K., Hata, J., Kusunoki, H., Sasaki, A., Ito,
M., Tanaka, S. & Yoshihara, M. The long-term effect of
Helicobacter pylori eradication therapy on symptoms in
dyspeptic patients with fundic atrophic gastritis, 245
- Kamm, M.A. *see* Bell, S.J.
- Kamm, M.A. *see* Rayner, C.K.
- Kamm, M.A. *see* Tytgat, G.N.
- Kasper, H.-U. *see* Juhász, M.
- Katz, P.O., Castell, D.O. & Levine, D. Esomeprazole resolves
chronic heartburn in patients without erosive oesophagitis,
875
- Kaya, D. *see* Ellidokuz, E.

- Keefe, E.B. *see* Zaman, A.
 Kellett, N. *see* Rordorf, C.
 Kellner, U. *see* Juhász, M.
 Kennedy, M.A. *see* Gearry, R.B.
 Kent, J.D. *see* Goldstein, J.L.
 Kerckhaert, J.A.M. *see* Goerres, M.S.
 Khorrami, S. *see* Gisbert, J.P.
 Kim, J.S. *see* Kim, S.G.
 Kim, S.G., Kim, J.S., Jung, H.C. & Song, I.S. Is a 9-month treatment sufficient in tuberculous enterocolitis? A prospective, randomized, single-centre study, 85
 Kirsch, C. *see* Miehke, S.
 Kivitz, A.J. *see* Goldstein, J.L.
 Kleibeuker, J.H. *see* Haagsma, E.B.
 Kng, C. *see* Ng, F.H.
 Koch, L. *see* Schiedermaier, P.
 Kohn, S. *see* Isomoto, H.
 Kositchaiwat, C., Ovartharnporn, B., Kachintorn, U. & Atisook, K. Low and high doses of rabeprazole vs. omeprazole for cure of *Helicobacter pylori* infection, 1017
 Kreisel, W. *see* Deibert, P.
 van Krieken, J.H.J.M. *see* Goerres, M.S.
 Kulig, M., Leodolter, A., Vieth, M., Schulte, E., Jaspersen, D., Labenz, J., Lind, T., Meyer-Sabellek, W., Malfetheriner, P., Stolte, M. & Willich, S.N. Quality of life in relation to symptoms in patients with gastro-oesophageal reflux disease — an analysis based on the ProGERD initiative, 767
 Kumar, D. *see* Davis, K.
 Kunz, P. *see* Steingoetter, A.
 Kurnik, D., Loebstein, R., Fishbein, E., Almog, S., Halkin, H., Bar-Meir, S. & Chowers, Y. Bioavailability of oral vs. subcutaneous low-dose methotrexate in patients with Crohn's disease, 57
 Kuroiwa, T. *see* Shimatani, T.
 Kusunoki, H. *see* Kamada, T.
 Kwok, K.F. *see* Lai, K.C.

 Labenz, J. *see* Kulig, M.
 Labigne, A. *see* Lamouliatte, H.
Lactobacillus johnsonii, 805
Lactobacillus plantarum 299v, 495
lafutidine, 1151
 Laheij, R.J.F., Van Ijzendoorn, M.C., Janssen, M.J.R. & Jansen, J.B.M.J. Gastric acid-suppressive therapy and community-acquired respiratory infections, 847
 Laheij, R.J.F., van Rossum, L.G.M., Jansen, J.B.M.J. & Verheugt, F.W.A. Proton-pump inhibitor therapy for acetylsalicylic acid associated upper gastrointestinal symptoms: a randomized placebo-controlled trial, 109
 Lai, K.C. *see* Wong, B.C.-Y.
 Lai, K.C. *see* Wong, W.M.
 Lai, K.C., Lam, S.K., Chu, K.M., Hui, W.M., Kwok, K.F., Wong, B.C.Y., Hu, H.C., Wong, W.M., Chan, O.O. & Chan, C.K. Lansoprazole reduces ulcer relapse after eradication of *Helicobacter pylori* in nonsteroidal anti-inflammatory drug users — a randomized trial, 829
 de Lalla, F. *see* Fabris, P.
 Lam, C.L.K. *see* Wong, W.M.
 Lam, K.F. *see* Wong, W.M.
 Lam, S.K. *see* Cheng, C.
 Lam, S.K. *see* Lai, K.C.
 Lam, S.K. *see* Wong, B.C.-Y.
 Lam, S.K. *see* Wong, W.M.
 Lamouliatte, H., Mégraud, F., Delchier, J.-C., Bretagne, J.-F., Courillon-Mallet, A., De Korwin, J.-D., Fauchère, J.-L., Labigne, A., Fléjou, J.-F. & Barthelemy (for a Multicentre Study Group), P. Second-line treatment for failure to eradicate *Helicobacter pylori*: a randomized trial comparing four treatment strategies, 791
 Lanas, A.I. *see* Ng, F.H.
 Lang, H.-C. *see* Lu, C.-L.
lansoprazole, 829, 1131
 Lapenna, D. *see* Neri, M.
 Laterza, F. *see* Neri, M.
 Lau, W.H. *see* Lee, K.K.C.
 Lauritsen, K. *see* Bolling-Sternevald, E.
 Law, W.L. *see* Wong, B.C.-Y.
laxatives, 291
 Layer, G. *see* Schiedermaier, P.
 Layer, P. *see* Malfetheriner, P.
 Lee, K.-J., Vos, R., Janssens, J. & Tack, J. Differential effects of baclofen on lower oesophageal sphincter pressure and proximal gastric motility in humans, 199
 Lee, K.K.C., You, J.H.S., Ho, J.T.S., Suen, B.Y., Yung, M.Y., Lau, W.H., Lee, V.W.Y., Sung, J.Y. & Chan, F.K.L. Economic analysis of celecoxib versus diclofenac plus omeprazole for the treatment of arthritis in patients at risk of ulcer disease, 217
 Lee, S.-D. *see* Lu, C.-L.
 Lee, V.W.Y. *see* Lee, K.K.C.
 Lehn, N. *see* Miehke, S.
 Lémann, M. *see* Bonaz, B.
 Lemann, M. *see* Gornet, J.-M.
 Lémann, M. *see* Sabaté, J.-M.
 Lendeckel, U. *see* Juhász, M.
 Lengsfeld, H. *see* Steingoetter, A.
 Leodolter, A. *see* Kulig, M.
 Leodolter, A. *see* Malfetheriner, P.
 Leodolter, A., Vaira, D., Bazzoli, F., Schütze, K., Hirschl, A., Mégraud, F. & Malfetheriner, P. European multicentre validation trial of two new non-invasive tests for the detection of *Helicobacter pylori* antibodies: urine-based ELISA and rapid urine test, 927
 Leung, P.-C. *see* Chan, H.L.-Y.
 Levine, D. *see* Katz, P.O.
levofloxacin, 627, 815
 Lièvre, A. *see* Buecher, B.
 Lima, J.C.P. *see* Gené, E.
 Lin, C.-Y. *see* Chi, C.-H.
 Lind, T. *see* Kulig, M.
 Lionetti, P., Bronzini, F., Salvestrini, C., Bascietto, C., Berni Canani, R., Dé Angelis, G.L., Guariso, G., Martellosi, S., Papadatou, B. & Barabino, A. Response to infliximab is related to disease duration in paediatric Crohn's disease, 425
 Liu, L., Ergun, G., Ertan, A., Woods, K., Sachs, I. & Younes, M. Detection of oxidative DNA damage in oesophageal biopsies of

- patients with reflux symptoms and normal pH monitoring, 693
- liver, 451
- liver cirrhosis, 357
- liver descriptors, 253, 661, 995
- liver failure, 473, 979
- liver function, 995
- liver functional mass, 785
- liver regeneration, 473
- liver transplantation, 33
- Loebstein, R. *see* Kurnik, D.
- long-term treatment, 569
- lower oesophageal sphincter, 199, 699
- loxiglumide, 333
- Lu, C.-L., Chen, C.-Y., Lang, H.-C., Luo, J.-C., Wang, S.-S., Chang, F.-Y. & Lee, S.-D. Current patterns of irritable bowel syndrome in Taiwan: the Rome II questionnaire on a Chinese population, 1159
- lumiracoxib, 533
- Luo, J.-C. *see* Lu, C.-L.
- Luypaerts, A. *see* Geboes, K.P.
- Maconi, G. *see* Parente, F.
- Maconi, G., Carsana, L., Fociani, P., Sampietro, G.M., Ardizzone, S., Cristaldi, M., Parente, F., Vago, G.L., Tashieri, A.M. & Bianchi Porro, G. Small bowel stenosis in Crohn's disease: clinical, biochemical and ultrasonographic evaluation of histological features, 749
- Madalinski, M., Siproudhis, L., Bellissant, E., Matsumoto, A., Izumiya, T., Takimoto, K., Inokuchi, H., Rajendra, S., Ho, J.J., Candelli, M., Cazzato, I.A., Nista, E.C., Pignataro, G., Gasbarrini, A., Furuta, T., Shirai, N., Sugimoto, M., Ohashi, K. & Ishizaki, T. Letter to the Editors, 1171
- Mäder, K. *see* Steingoetter, A.
- Magalini, S.C. *see* Gui, D.
- magnetic resonance imaging, 713
- Mahadevan, U., Marion, J.F. & Present, D.H. Fistula response to methotrexate in Crohn's disease: a case series, 1003
- Mair, S. *see* Rordorf, C.
- Malagelada, J.R. *see* Corazzari, E.
- Malekzadeh, R. *see* Shahbakhani, B.
- Malesci, A., Pezzilli, R., D'Amato, M. & Rovati, L. CCK-1 receptor blockade for treatment of biliary colic: a pilot study, 333
- Mallfertheiner, P. *see* Juhász, M.
- Mallfertheiner, P. *see* Kulig, M.
- Mallfertheiner, P. *see* Leodolter, A.
- Mallfertheiner, P., Mössner, J., Fischbach, W., Lauer, P., Leodolter, A., Stolte, M., Demleitner, K. & Fuchs, W. *Helicobacter pylori* eradication is beneficial in the treatment of functional dyspepsia, 615
- Manguso, F. *see* Castiglione, F.
- Mannheimer, C. *see* Borjesson, M.
- Marchildon, P. *see* Bergey, B.
- Marciani, L. *see* Coleman, N.S.
- Måre, K. *see* Arlander, E.
- Marion, J.F. *see* Mahadevan, U.
- Marteau, P. *see* Bonaz, B.
- Marteau, P. *see* Gornet, J.-M.
- Martelossi, S. *see* Lionetti, P.
- Martin, P. *see* Fabrizi, F.
- Martínez-Delgado, C. *see* Romero-Gómez, M.
- Matsumoto, A. *see* Madalinski, M.
- May, A. *see* Trebble, T.M.
- Mazzacca, G. *see* Castiglione, F.
- McCallum, R.W. *see* Pehlivanov, N.D.
- McCormack, G. *see* Rayner, C.K.
- McGovern, J. *see* Beales, I.L.P.
- McKinzie, S. *see* Delgado-Aros, S.
- meal size, 507
- median intragastric pH value, 1151
- medications, 907
- Mégraud, F. *see* Bergey, B.
- Mégraud, F. *see* Lamouliatte, H.
- Mégraud, F. *see* Leodolter, A.
- Meijer, J.W.R. *see* Goerres, M.S.
- Merat, S. *see* Shahbakhani, B.
- Merla, A. *see* Perri, F.
- mesalamine, 263
- mesalazine, 191
- meta-analysis, 167, 279, 543, 757, 1071
- metabolic activity, 495
- metadoxine, 357
- methotrexate, 57, 1003
- Metman, E.-H. *see* Bonaz, B.
- metronidazole, 101, 263, 347, 799, 1107
- Meyer-Sabellek, W. *see* Kulig, M.
- microvessel density, 837
- Miehlke, S., Schneider-Brachert, W., Bästlein, E., Ebert, S., Kirsch, C., Haferland, C., Buchner, M., Neumeyer, M., Vieth, M., Stolte, M., Lehn, N. & Bayerdörffler, E. Esomeprazole-based one-week triple therapy with clarithromycin and metronidazole is effective in eradicating *Helicobacter pylori* in the absence of antimicrobial resistance, 799
- Miehsler, W. *see* DeJaco, C.
- Mieno, H. *see* Shimatani, T.
- Miglioli, M. *see* Calabrese, C.
- Milano, A. *see* Neri, M.
- Milosavljev, S. *see* Rordorf, C.
- Miner Jr, P.B. *see* Gardner, J.D.
- mitogen-activated protein kinases, 17
- Mizuta, Y. *see* Isomoto, H.
- MKC-733, 1039
- Modigliani, R. *see* Gornet, J.-M.
- Modigliani, R. *see* Sabaté, J.-M.
- Molteni, M. *see* Parente, F.
- Montojo, C. *see* Romero-Gómez, M.
- Moorghe, M. *see* Creed, T.J.
- Morini, S. *see* Hassan, C.
- morphology, 693
- Morris, J. *see* Corazzari, E.
- Mosnier, J.-F. *see* Buecher, B.
- Mössner, J. *see* Mallfertheiner, P.
- motility, 319
- motility and nerve-gut interactions, 77, 515, 671, 721

- Mouncher, A. *see* Ahmad, I.
 mouth, 853
 mucosa, 853
 Mulder, C.J.J. *see* Goerres, M.S.
 Mullee, M.A. *see* Trebble, T.M.
 Muller-Lissner, S. *see* Corazzari, E.
 Müller-Lissner, S. *see* Tytgat, G.N.
 multiple PCR assays, 481
 Murase, K. *see* Isomoto, H.
 Murata, I. *see* Isomoto, H.
 myocardial infarction, 973
- Naesdal, J. *see* Dunlop, S.P.
 Nakaizumi, A. *see* Sakai, N.
 Nakamura, M. *see* Shimatani, T.
 naproxen, 125, 533
 Nasserimoghadam, S. *see* Shahbazkhani, B.
 Nauck, S. *see* Deibert, P.
 Navarro, J.-M. *see* Romero-Gómez, M.
 Neal, K.R. *see* Dunlop, S.P.
 Neoptolemos, J.P. *see* Shore, S.
 Neri, M., Milano, A., Laterza, F., Di Bonaventura, G., Piccolomini, R., Caldarella, M.P., Balatsinou, C., Lapenna, D. & Cuccurullo, F. Role of antibiotic sensitivity testing before first-line *Helicobacter pylori* eradication treatments, 821
 Neumeyer, M. *see* Miehlke, S.
 Nevin, K. *see* Armstrong, D.
 Ng, F.H., Wong, S.Y., Chang, C.M., Chen, W.H., Kng, C., Lanas, A.I. & Wong, B.C.Y. High incidence of clopidogrel-associated gastrointestinal bleeding in patients with previous peptic ulcer disease, 443
 Nguyen, J.-M. *see* Buecher, B.
 Niro, G.A., Santantonio, T., Fontana, R., Insalata, M., Facciorusso, D., Signorile, F., Perri, F., Guastadisegni, A., Gioffreda, D., Palmieri, O., Pastore, G. & Andriulli, A. Re-treatment of patients with anti-HBe-positive chronic hepatitis B who relapsed after an initial course of lamivudine, 933
 Nista, E.C. *see* Madalinski, M.
 Nista, E.C., Candelli, M., Cremonini, F., Cazzato, I.A., Di Caro, S., Gabrielli, M., Santarelli, L., Zocco, M.A., Ojetti, V., Carloni, E., Cammarota, G., Gasbarrini, G. & Gasbarrini, A. Levofloxacin-based triple therapy vs. quadruple therapy in second-line *Helicobacter pylori* treatment: a randomized trial, 627
 nocturnal gastric acid breakthrough, 883
 non-erosive gastro-oesophageal reflux disease, 605
 non-erosive oesophagitis, 525
 non-erosive reflux disease, 1091
 non-pathogenic *E. coli* Nissle 1917, 45
 non-surgical gallstone therapy, 963
 non-ulcer dyspepsia, 117, 245, 635
 Norman, A.R. *see* Gami, B.
 Norman, M.R. *see* Creed, T.J.
 NSAID, 125, 217, 829, 1139
 nutcracker oesophagus, 1131
 nutritional status, 433
 nutritional therapy, 357
 oesophageal motility, 1083
 oesophageal pH, 891
 oesophageal pH monitoring, 883, 1091
 oesophageal/gastric/duodenal disorders, 891, 1023
 oesophagitis, 545, 693, 875
 Ohashi, K. *see* Madalinski, M.
 Ojetti, V. *see* Nista, E.C.
 Oliveira, A.G. *see* Gené, E.
 Olyae, M. *see* Pehlivanov, N.D.
 Omagari, K. *see* Isomoto, H.
 omeprazole, 757, 799, 821, 1017, 1151
 O'Morain, C.A. *see* Sebastian, S.
 once-daily therapy, 93
 oral bioavailability, 57
 oral ulceration, 949
 osteoporosis, 1121
 outcome measure, 569
 Ovarthlarnporn, B. *see* Kositchaiwat, C.
 Owen, R.J. *see* Bell, S.J.
 oxidative damage, 693
- p53, 837
 paediatric, 433
 Pajares, J.M. *see* Gisbert, J.P.
 Pallone, F. *see* Cicala, M.
 Palmer, R.C. *see* Goldstein, J.L.
 Palmieri, O. *see* Niro, G.A.
 pancreatic cancer, 1049
 pancreatitis, 401
 Panella, C. *see* Hassan, C.
 Pantolickova, D., Corthésy-Theulaz, I., Dorta, G., Stolte, M., Isler, P., Rochat, F., Enslin, M. & Blum, A.L. Favourable effect of regular intake of fermented milk containing *Lactobacillus johnsonii* on *Helicobacter pylori* associated gastritis, 805
 pantoprazole, 587, 705
 Papadakis, K.A., Treyzon, L., Abreu, M.T., Fleshner, P.R., Targan, S.R. & Vasiliauskas, E.A. Infliximab in the treatment of medically refractory indeterminate colitis, 741
 Papadatou, B. *see* Lionetti, P.
 paracetamol, 979
 parental nutrition, 357
 Parente, F. *see* Maconi, G.
 Parente, F., Greco, S., Molteni, M., Cucino, C., Maconi, G., Sampietro, G.M., Danelli, P.G., Cristaldi, M., Bianco, R., Gallus, S. & Bianchi Porro, G. Role of early ultrasound in detecting inflammatory intestinal disorders and identifying their anatomical location within the bowel, 1009
 Parker, M. *see* Coleman, N.S.
 Parsi, M.A. *see* Saadeh, S.
 Pastore, G. *see* Niro, G.A.
 Pastorekova, S. *see* Juhász, M.
 patient satisfaction, 907
 patient-reported outcomes, 907
 Peacock, J. *see* Bergey, B.
 Pearson, T. *see* Dekel, R.
 Peaston, R.T. *see* Bartram, S.A.

- Pehlivanov, N.D., Olyae, M., Sarosiek, I. & McCallum, R.W.
Comparison of morning and evening administration of
rabeprazole for gastro-oesophageal reflux and nocturnal
gastric acid breakthrough in patients with reflux disease: a
double-blind, cross-over study, 883
- pelvic cancer, 987
- pelvic radiotherapy, 987
- Penagini, R. *see* Cantù, P.
- peptic ulcer disease, 93, 443, 647
- percutaneous endoscopic gastrostomy, 209
- percutaneous endoscopic gastrostomy, 947
- perianal disease activity index, 1113
- perianal fistulas, 1113
- peristomal infection, 209
- Perkins, A.C. *see* Coleman, N.S.
- Perri, F. *see* Niro, G.A.
- Perri, F., Festa, V., Merla, A., Barberani, F., Pilotto, A. & Andriulli, A.
Randomized study of different 'second-line' therapies for
Helicobacter pylori infection after failure of the standard
'Maastricht triple therapy', 815
- Petritti, T. *see* Cicala, M.
- Petritsch, W. *see* Högenauer, C.
- Petrolati, A., Festi, D., De Berardinis, G., Colaiocco-Ferrante, L., Di
Paolo, D., Tisone, G. & Angelico, M. ¹³C-methacetin breath
test for monitoring hepatic function in cirrhotic patients before
and after liver transplantation, 785
- Pezzilli, R. *see* Malesci, A.
- pH > 4 holding time ratio, 1151
- pharmacodynamics, 705
- pharmacogenetics, 395
- pharmacokinetics, 183, 705
- Phelip, J.-M. *see* Roblin, X.
- pH-monitoring, 545, 605
- Phung, D.C. *see* Wheeldon, T.-U.
- Phyllanthus urinaris*, 339
- Piccolomini, R. *see* Neri, M.
- Piglioni, D. *see* Hassan, C.
- Pignataro, G. *see* Madalinski, M.
- Pigot, F. *see* Siprodhis, L.
- Pihall, M. *see* Borjesson, M.
- Pilotto, A. *see* Perri, F.
- Pittler, M.H. & Ernst, E. Systematic review: hepatotoxic events
associated with herbal medicinal products, 451
- placebo, 1173
- pneumonia, 847
- Poloniecki, J. *see* Davis, K.
- polyenylphosphatidylcholine, 357
- population survey, 595
- portal hypertension, 777
- portal pressure, 777
- post-infective irritable bowel syndrome, 77
- predictive factors, 33
- prednisone, 263
- pregnancy, 291
- premedication, 327
- Present, D.H. *see* Mahadevan, U.
- prevalence, 33, 1161
- primary biliary cirrhosis, 963
- Probert, C.S.J. *see* Creed, T.J.
- probiotic, 45
- probiotic drink, 495
- prognosis, 223, 731
- prognostic factors, 117
- pronase, 327
- protein malnutrition, 357
- proton pump inhibitor therapy, 109
- proton pump inhibitors, 117, 133, 217, 559, 587, 647, 757, 847,
875, 1139
- proximal gastric motility, 199
- QT, 151
- quadruple therapy, 347, 543, 815
- quality of life, 587, 767
- Queiroz, D.M.M. *see* Gené, E.
- rabeprazole, 101, 883, 1017
- radiotherapy, 853
- Rajendra, S. *see* Madalinski, M.
- randomized clinical trial, 515
- randomized controlled trial, 1099
- ranitidine, 757
- ranitidine bismuth citrate, 815, 821
- Raraty, M.G.T. *see* Shore, S.
- Rawlings, D.J. *see* Bartram, S.A.
- Rayner, C.K., McCormack, G., Emmanuel, A.V. & Kamm, M.A.
Long-term results of low-dose intravenous ciclosporin for acute
severe ulcerative colitis, 303
- Recker, D.P. *see* Goldstein, J.L.
- rectal administration, 655
- rectal cancer, 941
- recurrence, 443
- reflux disease, 279
- reflux oesophagitis, 587
- Reinisch, W. *see* Dejaco, C.
- Rentz, A.M. *see* Revicki, D.A.
- replication error phenotype, 731
- rescue treatment, 815
- respiratory infection, 847
- re-treatment, 815, 933
- retrograde colonic spread, 655
- Revicki, D. *see* Coyne, K.S.
- Revicki, D.A., Rentz, A.M., Dubois, D., Kahrilas, P., Stanghellini,
V., Talley, N.J. & Tack, J. Development and validation of a
patient-assessed gastroparesis symptom severity measure: the
Gastroparesis Cardinal Symptom Index, 141
- Reynaert, H. & Geerts, A. Review article: pharmacological
rationale for the use of somatostatin and analogues in portal
hypertension, 375
- Ribolsi, M. *see* Cicala, M.
- right upper quadrant pain, 167
- Riley, S.A. *see* Shale, M.J.
- Rispo, A. *see* Castiglione, F.
- Roberts, R.L. *see* Geary, R.B.
- Robinson, M. *see* Gardner, J.D.

- Roblin, X., Serre-Debeauvais, F., Phelip, J.-M., Bessard, G. & Bonaz, B. Drug interaction between infliximab and azathioprine in patients with Crohn's disease, 917
- Rocha, G.A. *see* Gené, E.
- Rochat, F. *see* Pantoflickova, D.
- Rolny, P. *see* Borjesson, M.
- Rome criteria, 1161
- Romero-Gómez, M., Martínez-Delgado, C., Hergueta, P., Navarro, J.-M., Garrido-Serrano, A., Santos, O. & Montojo, C. Three-day intravenous triple therapy is not effective for the eradication of *Helicobacter pylori* infection in patients with bleeding gastroduodenal ulcer, 1023
- ropivacaine, 655
- Rordorf, C., Kellett, N., Mair, S., Ford, M., Milosavljev, S., Branson, J. & Scott, G. Gastrointestinal tolerability of lumiracoxib vs. placebo and naproxen: a pilot endoscopic study in healthy male subjects, 533
- Rossi, S. *see* Gui, D.
- van Rossum, L.G.M. *see* Laheij, R.J.F.
- Rovati, L. *see* Malesci, A.
- Rozen, P. *see* Wong, B.C.-Y.
- Ruigómez, A. *see* Johansson, S.
- Runfola, M. *see* Gui, D.
- Russel, M. *see* Goossens, D.
- Rutgeerts, P. *see* Geboes, K.P.
- Saadah, S., Behrens, P.W., Parsi, M.A., Carey, W.D., Connor, J.T., Grealis, M. & Barnes, D.S. The utility of the ^{13}C -galactose breath test as a measure of liver function, 995
- Sabaté, J.-M., Villarejo, J., Bouhnik, Y., Allez, M., Gornet, J.-M., Vahedi, K., Modigliani, R. & Lémann, M. Hydrostatic balloon dilatation of Crohn's strictures, 409
- Sachs, I. *see* Liu, L.
- S-adenosyl-L-methionine, 357
- safety, 451
- safety, 791
- Sakai, N., Tatsuta, M., Iishi, H. & Nakaizumi, A. Pre-medication with pronase reduces artefacts during endoscopic ultrasonography, 327
- Salter, J. *see* Tack, J.
- Salvestrini, C. *see* Lionetti, P.
- Sampietro, G.M. *see* Maconi, G.
- Sampietro, G.M. *see* Parente, F.
- Sandborn, W.J. & Feagan, B.G. Review article: mild to moderate Crohn's disease – defining the basis for a new treatment algorithm, 263
- Santantonio, T. *see* Niro, G.A.
- Santarelli, L. *see* Nista, E.C.
- Santos, O. *see* Romero-Gómez, M.
- Sarosiek, I. *see* Pehlivanov, N.D.
- Sasaki, A. *see* Kamada, T.
- Sauerbruch, T. *see* Schiedermaier, P.
- Savarino, V. *see* Frazzoni, M.
- Savojardo, D. *see* Cantù, P.
- Scaccianoce, G. *see* Hassan, C.
- Schiedermaier, P., Koch, L., Stoffel-Wagner, B., Layer, G. & Sauerbruch, T. Effect of propranolol and depot lanreotide SR on postprandial and circadian portal haemodynamics in cirrhosis, 777
- Schmidt, L.E. & Dalhoff, K. The impact of current tobacco use on the outcome of paracetamol poisoning, 979
- Schmier, J. *see* Coyne, K.S.
- Schneider-Brachert, W. *see* Miehke, S.
- Schölmerich, J. *see* Tytgat, G.N.
- Scholten, T., Gatz, G. & Hole, U. Once-daily pantoprazole 40mg and esomeprazole 40mg have equivalent overall efficacy in relieving GERD-related symptoms, 587
- Schreiber, S. *see* Waetzig, G.H.
- Schulte, E. *see* Kulig, M.
- Schuppan, D. *see* Stickel, F.
- Schütze, K. *see* Leodolter, A.
- Schwizer, W. *see* Steingotter, A.
- Scialpi, C. *see* Calabrese, C.
- sclerosing cholangitis, 963
- Scott, G. *see* Rordorf, C.
- screening, 941
- Sebastian, S., O'Morain, C.A. & Buckley, M.J.M. Review article: current therapeutic options for gastric antral vascular ectasia, 157
- Sébillé, V. *see* Siprodhis, L.
- second-line therapy, 101
- second-line treatment, 627, 791
- Seitz, H.K. *see* Stickel, F.
- self-poisoning, 979
- sensation, 507
- Sepulveda, A. *see* Cremonini, F.
- sequential treatment, 641
- serology, 635
- Serre-Debeauvais, F. *see* Roblin, X.
- Shahbazkhani, B., Forootan, M., Merat, S., Akbari, M.R., Nasserimoghadam, S., Vahedi, H. & Malekzadeh, R. Coeliac disease presenting with symptoms of irritable bowel syndrome, 231
- Shale, M.J. & Riley, S.A. Studies of compliance with delayed-release mesalazine therapy in patients with inflammatory bowel disease, 191
- Shaw, I.S. *see* Creed, T.J.
- Shepherd, N.A. *see* Creed, T.J.
- Sheu, B.-S. *see* Chi, C.-H.
- Shimada, S. *see* Isomoto, H.
- Shimatani, T., Inoue, M., Kuroiwa, T., Horikawa, Y., Mieno, H. & Nakamura, M. Effect of omeprazole 10 mg on intragastric pH in three different CYP2C19 genotypes, compared with omeprazole 20 mg and lafutidine 20 mg, a new H_2 -receptor antagonist, 1149
- Shirai, N. *see* Madalinski, M.
- Shore, S., Raraty, M.G.T., Ghaneh, P. & Neoptolemos, J.P. Review article: chemotherapy for pancreatic cancer, 1049
- short-term treatment, 569
- side effects, 549, 627, 847
- Signorile, F. *see* Niro, G.A.
- Silva, C.P. *see* Gené, E.
- sinicalide, 167

- Siprodhis, L., Sébille, V., Pigot, F., Hémerly, P., Juguet, F. & Bellissant, E. Lack of efficacy of botulinum toxin in chronic anal fissure, 515
- Siproudhis, L. *see* Madalinski, M.
- Skammer, W. *see* Sostek, M.B.
- Sloan, S. *see* Gardner, J.D.
- Slooff, M.J.H. *see* Haagsma, E.B.
- Smithson, J. *see* Creed, T.J.
- smoking, 979
- Song, I.S. *see* Kim, S.G.
- Sörberg, M. *see* Wheeldon, T.-U.
- Sostek, M.B., Chen, Y., Skammer, W., Winter, H., Zhao, J. & Andersson, T. Esomeprazole administered through a nasogastric tube provides bioavailability similar to oral dosing, 581
- Sozzi, M. *see* Gené, E.
- SPECT, 507
- sphincter bulking, 237
- sphincter of Oddi dysfunction, 1
- sphincterotomy, 1173
- Spiller, R.C. *see* Coleman, N.S.
- Spiller, R.C. *see* Corazziari, E.
- Spiller, R.C. *see* Dunlop, S.P.
- splanchnic circulation, 777
- Stanghellini, V. *see* Revicki, D.A.
- Steingoetter, A., Kunz, P., Weishaupt, D., Mäder, K., Lengsfeld, H., Thumshirn, M., Boesiger, P., Fried, M. & Schwizer, W. Analysis of the meal-dependent intragastric performance of a gastric-retentive tablet assessed by magnetic resonance imaging, 713
- stem cell, 473
- stenosis, 749
- Stenson, R. *see* Ahmad, I.
- steroid resistance, 65
- Stickel, F., Hoehn, B., Schuppan, D. & Seitz, H.K. Review article: nutritional therapy in alcoholic liver disease, 357
- Stobberingh, E. *see* Goossens, D.
- Stockbrügger, R. *see* Goossens, D.
- Stoelben, S. *see* Deibert, P.
- Stoffel-Wagner, B. *see* Schiedermaier, P.
- Stolte, M. *see* Kulig, M.
- Stolte, M. *see* Malfertheiner, P.
- Stolte, M. *see* Miehlke, S.
- Stolte, M. *see* Pantoflickova, D.
- stomach, 713
- stricture, 409
- Stroud, M.A. *see* Trebble, T.M.
- Sturkenboom, M.C.J.M., Burke, T.A., Tangelder, M.J.D., Dieleman, J.P., Walton, S. & Goldstein, J.L. Adherence to proton pump inhibitors or H₂-receptor antagonists during the use of non-steroidal anti-inflammatory drugs, 1137
- subgroups, 223
- Suen, B.Y. *see* Lee, K.K.C.
- Sugimoto, M. *see* Madalinski, M.
- Sugiyama, T. *see* Gené, E.
- sulfasalazine, 263
- sulphonamide, 837
- Sung, J.J.-Y. *see* Chan, H.L.-Y.
- Sung, J.Y. *see* Lee, K.K.C.
- superparamagnetic contrast marker, 713
- symptoms, 587
- tablet performance, 713
- Tack, J. *see* Corazziari, E.
- Tack, J. *see* Lee, K.-J.
- Tack, J. *see* Revicki, D.A.
- Tack, J., Vos, R., Janssens, J., Salter, J., Jauffret, S. & Vandeplasche, G. Influence of tegaserod on proximal gastric tone and on the perception of gastric distension, 1031
- Taillard, F. *see* Gornet, J.-M.
- Tait, D. *see* Gami, B.
- Takimoto, K. *see* Madalinski, M.
- Talley, N.J. *see* Bolling-Sternevald, E.
- Talley, N.J. *see* El-Serag, H.B.
- Talley, N.J. *see* Revicki, D.A.
- Tanaka, S. *see* Kamada, T.
- Tangelder, M.J.D. *see* Sturkenboom, M.C.J.M.
- Tanser, L. *see* Armstrong, D.
- Targan, S.R. *see* Papadakis, K.A.
- Taschieri, A.M. *see* Maconi, G.
- Tatsuta, M. *see* Sakai, N.
- tegaserod, 1031
- therapy, 757
- therapy, 799
- thioguanine, 183, 401
- thiopurine methyltransferase, 395
- Thomas, G. *see* Ahmad, I.
- Thomas, R.R. *see* Gill, S.
- Thompson, N.P. *see* Bartram, S.A.
- Thomson, A.B.R. *see* Wild, G.E.
- Thumshirn, M. *see* Steingoetter, A.
- Tillett, J. *see* Ahmad, I.
- Tisone, G. *see* Petrolati, A.
- tobacco, 979
- Tong, T.S.M. *see* Wong, B.C.-Y.
- Tosititi, G. *see* Fabris, P.
- transient lower oesophageal sphincter relaxation, 199
- transmission electron microscopy, 525
- treatment, 543, 767, 837
- treatment guidelines, 291
- treatment satisfaction, 907
- treatment-response, 1099
- Trebbles, T.M., Wootton, S.A., May, A., Erlewyn-Lajeunesse, M.D.S., Chakraborty, A., Mullee, M.A., Stroud, M.A. & Beattie, R.M. Essential fatty acid status in paediatric Crohn's disease: relationship with disease activity and nutritional status, 433
- Treyzon, L. *see* Papadakis, K.A.
- Tripathi, D. *see* Ferguson, J.W.
- triple therapy, 347, 543, 647, 815
- tuberculosis, 85
- Tulassay, Z. *see* Juhász, M.
- Tung, H.M. *see* Wong, B.C.-Y.
- type 1 diabetes, 549
- Tytgat, G.N., Heading, R.C., Müller-Lissner, S., Kamm, M.A., Schölmerich, J., Berstad, A., Fried, M., Chaussade, S., Jewell, D.

- & Briggs, A. Contemporary understanding and management of reflux and constipation in the general population and pregnancy: a consensus meeting, 291
- ulcer, 533, 829
- ulcer healing, 93
- ulcerative colitis, 175, 395, 481, 741, 1009
- ultrasound, 749
- upper gastrointestinal symptoms, 109
- urine, 927
- Vago, G.L. *see* Maconi, G.
- Vahedi, H. *see* Shahbazkhani, B.
- Vahedi, K. *see* Sabaté, J.-M.
- Vaira, D. *see* Leodolter, A.
- Vakil, N. & Fennerty, M.B. Systematic review: direct comparative trials of the efficacy of proton pump inhibitors in the management of gastro-oesophageal reflux disease and peptic ulcer disease, 559
- valdecixib, 125
- Vallve, M. *see* Vergara, M.
- Van Den Berg, A.P. *see* Haagsma, E.B.
- Van Ijzendoorn, M.C. *see* Laheij, R.J.F.
- Vandeplassche, G. *see* Tack, J.
- Vasiliauskas, E.A. *see* Papadakis, K.A.
- Vavassori, P. *see* Cicala, M.
- Verbeke, K. *see* Geboes, K.P.
- Verburg, K.M. *see* Goldstein, J.L.
- Vergani, D. *see* Fabris, P.
- Vergara, M., Vallve, M., Gisbert, J.P. & Calvet, X. Meta-analysis: comparative efficacy of different proton-pump inhibitors in triple therapy for *Helicobacter pylori* eradication, 647
- Verheugt, F.W.A. *see* Laheij, R.J.F.
- Vieth, M. *see* Kulig, M.
- Vieth, M. *see* Miehle, S.
- Vietnam, 93
- Villarejo, J. *see* Sabaté, J.-M.
- visceral, 507
- viscosity, 655
- visual analogue scale, 515
- Vogelsang, H. *see* Dejaco, C.
- Vos, R. *see* Lee, K.-J.
- Vos, R. *see* Tack, J.
- Waetzig, G.H. & Schreiber, S. Review article: mitogen-activated protein kinases in chronic intestinal inflammation — targeting ancient pathways to treat modern diseases, 17
- Wahab, P.J. *see* Goerres, M.S.
- waiting list, 785
- Waldhoer, T. *see* Dejaco, C.
- Wallander, M.-A. *see* Johansson, S.
- Walton, S. *see* Sturkenboom, M.C.J.M.
- Wang, S.-S. *see* Lu, C.-L.
- Waschke, K.A. *see* Wild, G.E.
- Weishaupt, D. *see* Steingotter, A.
- Wendel, C. *see* Dekel, R.
- Wenzl, H.H. *see* Högenauer, C.
- Wheeldon, T.-U., Hoang, T.T.H., Phung, D.C., Björkman, A., Granström, M. & Sörberg, M. *Helicobacter pylori* eradication and peptic ulcer healing: the impact of deleting the proton pump inhibitor and using a once-daily treatment, 93
- Whorwell, P.J. *see* Corazzari, E.
- Wiklund, I. *see* Coyne, K.S.
- Wild, G.E., Waschke, K.A., Bitton, A. & Thomson, A.B.R. The mechanisms of prednisone inhibition of inflammation in Crohn's disease involve changes in intestinal permeability, mucosal TNF α production and nuclear factor kappa B expression, 309
- Wilde, K. *see* Coleman, N.S.
- Willich, S.N. *see* Kulig, M.
- Wilson, K. *see* Buecher, B.
- Windeck, T. *see* Holtmann, G.
- Winter, H. *see* Sostek, M.B.
- Wong, B.C.Y. *see* Lai, K.C.
- Wong, B.C.Y. *see* Ng, F.H.
- Wong, B.C.Y. *see* Wong, W.M.
- Wong, B.C.-Y., Wong, W.M., Cheung, K.L., Tong, T.S.M., Rozen, P., Young, G.P., Chu, K.W., Ho, J., Law, W.L., Tung, H.M., Lai, K.C., Hu, W.H.C., Chan, C.K. & Lam, S.K. A sensitive guaiac faecal occult blood test is less useful than an immunochemical test for colorectal cancer screening in a Chinese population, 941
- Wong, S.Y. *see* Ng, F.H.
- Wong, W.M. *see* Lai, K.C.
- Wong, W.M. *see* Wong, B.C.-Y.
- Wong, W.M., Lai, K.C., Lam, K.F., Hui, W.M., Hu, W.H.C., Lam, C.L.K., Xia, H.H.X., Huang, J.Q., Chan, C.K., Lam, S.K. & Wong, B.C.Y. Prevalence, clinical spectrum and health care utilization of gastro-oesophageal reflux disease in a Chinese population: a population-based study, 595
- Woods, K. *see* Liu, L.
- Wootton, S.A. *see* Trebble, T.M.
- Wright, J. *see* Ahmad, I.
- Wright, J. *see* Coleman, N.S.
- Wu, J.-J. *see* Chi, C.-H.
- Xia, H.H.X. *see* Wong, W.M.
- Yamakawa, M. *see* Isomoto, H.
- Yamazaki, S. *see* Coleman, N.S.
- Yang, H.-B. *see* Chi, C.-H.
- Yano, T. *see* Coleman, N.S.
- YMDD mutants, 933
- Yoshihara, M. *see* Kamada, T.
- You, J.H.S. *see* Lee, K.K.C.
- Younes, M. *see* Liu, L.
- Young, G.P. *see* Wong, B.C.-Y.
- Yung, M.Y. *see* Lee, K.K.C.
- Yung, P.-P. *see* Chan, H.L.-Y.
- Zaman, A., Fennerty, M.B. & Keeffe, E.B. Systematic review: peginterferon vs. standard interferon in the treatment of chronic hepatitis C, 661
- Zhao, J. *see* Sostek, M.B.
- Zocco, M.A. *see* Nista, E.C.
- Zullo, A. *see* Hassan, C.

